

FOR IMMEDIATE RELEASE

Listed Company Name: Kyowa Hakko Kirin Co., Ltd.

Representative: Nobuo Hanai, President and CEO

(Code no.: 4151, First Section of TSE)

Inquiries: Shigeru Morotomi, Managing Officer

Corporate Communications Department

Telephone: +81-3-3282-0009

Kyowa Hakko Kirin Establishes “Singapore Translational Research Laboratory (STRL)”

- Initiates Research Collaboration with the Cancer Science Institute of Singapore and the National University Cancer Institute, Singapore

Tokyo, Japan, September 9, 2013 – Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, “KHK”) today announced the setup of its new Singapore Translational Research Laboratory (STRL) under Kyowa Hakko Kirin (Singapore) Pte. Ltd. (KKSG), a wholly owned subsidiary of KHK.

KKSG has also initiated research collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) and the National University Cancer Institute, Singapore (NCIS) to jointly conduct oncology translational research in Singapore. This industry collaboration was structured and negotiated by NUS Industry Liaison Office, part of NUS Enterprise.

STRL, which will be located at the Biopolis, is an international research and development centre in Singapore for biomedical sciences, and will play a leading role in KHK’s global R&D efforts in translational research. STRL has initiated a joint collaborative research project with both NUS and NCIS. Under this project, STRL, CSI Singapore and the Yong Loo Lin School of Medicine at NUS, together with NCIS and the National University Hospital (NUH) will jointly conduct pre-clinical research on bio-molecular drugs developed by KHK and will explore biomarker candidates, which could facilitate and accelerate future clinical trials.

“We recognise Singapore’s strong expertise in oncology translational research and look forward to expanding our translational research programmes into the country. We are confident that this collaboration with CSI Singapore and NCIS will greatly accelerate our drug development programme and enhance the therapeutic value of our drug candidate. We also

look forward to partnerships and collaborations with other research groups in Singapore and beyond,” said Hiroshi Okazaki, Ph.D., Vice President and Head of Research Division of KHK.

“We are excited by this highly synergistic alliance. Leveraging on the expertise from the industry and academia, this initiative will generate vital pre-clinical and clinical knowledge needed to bring new drugs to our cancer patients,” said Dr Yong Wei Peng, Senior Consultant in the Department of Haematology-Oncology at NCIS. He is the lead principal investigator for the research.

Through this research collaboration, NCIS aims to find better ways to screen, diagnose and treat cancer. Today, cancer research and education efforts on campus are spearheaded by NCIS and CSI. This partnership will enable clinicians and scientists to work on high quality research projects and develop new therapeutic strategies which will benefit Asian patients.

“The establishment of KHK’s STRL is an excellent example of companies leveraging Singapore’s translational and clinical research ecosystem to accelerate the drug discovery and development process. We are delighted that KHK has chosen to work with Singapore, and we will continue to enhance our infrastructure and capabilities to enable companies to conduct translational research”, said Mr Kevin Lai, Director Biomedical Sciences, Singapore Economic Development Board.

STRL will also serve as KHK’s R&D hub to explore other research collaboration opportunities with research groups in Singapore.

As Japan’s leading biopharmaceutical company, KHK is committed to making steady R&D advances and developing new drugs to respond to the needs of patients suffering from diseases for which no effective treatments are available, their families, and healthcare professionals who are fighting the diseases at the front line.

[Outline of the new laboratory]

1. Name: Singapore Translational Research Laboratory
2. Location: 11 Biopolis Way, #05-08, Helios Singapore 138667
3. Floor area: 414.70 m²
4. Date of establishment: September 2013

ENDS

Media queries may be directed to:

Public Relations Group
Corporate Communications Dept.
Kyowa Hakko Kirin Co., Ltd.
Email: media@kyowa-kirin.co.jp

Ms Dawn Sim
NUHS Communications
National University Health System
Email: dawn_sim@nuhs.edu.sg
Tel: + 65 6772 3989, Mobile: +65 9230 6006

About Kyowa Hakko Kirin (KHK) and Kyowa Hakko Kirin Singapore (KKSG)

KHK is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. KHK leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world. KKSG is a wholly-owned Singapore subsidiary of KHK and serves as a sales and marketing company. For more information, visit <http://www.kyowa-kirin.com>.

About the National University of Singapore (NUS)

The National University of Singapore is a leading research-intensive university centred in Asia. Ranked in the top 30 worldwide, NUS offers a global approach to education and research, with a focus on Asian perspectives and expertise. NUS has three Research Centres of Excellence (RCE) and 23 university-level research institutes and centres. It is also a partner in Singapore's 5th RCE. NUS shares a close affiliation with 16 national-level research institutes and centres. Research activities are world class, and NUS is well-known for its research strengths in engineering, life sciences, medicine, social sciences, natural sciences and at the intersection of these disciplines to address issues such as ageing and sustainability.

For more information, please visit <http://www.nus.edu.sg/>.

About the Cancer Science Institute of Singapore

The Cancer Science Institute of Singapore (CSI Singapore) was officially launched on 15 October 2008. CSI Singapore aims to position Singapore as a global-leader in the field of Biomedical Sciences. Its mission: to conduct a multifaceted and coordinated approach to cancer research, extending from basic cancer studies all the way to experimental therapeutics and in so doing improve cancer treatment.

CSI Singapore is a state-of-the-art university research institute affiliated with, and hosted at the National University of Singapore. In 2008, it was awarded a \$172 million “Research Center of Excellence” grant, one of only five in Singapore, by the National Research Foundation and the Ministry of Education. Professor Daniel G Tenen, MD, was named its founding director. Professor Tenen is a leader in the field of transcriptional regulation, hematopoiesis, and cancer.

The institute is an anchor for research expertise in two broad programs; Cancer Biology & Stem Cells, and Experimental Therapeutics; these programs form expansive platforms for CSI Singapore’s focus on key cancer disease cancers in gastric, liver, lung and leukemia which are endemic in Asian populations.

About the National University Hospital

The NUH is a tertiary hospital and major referral centre for a comprehensive range of medical, surgical and dental specialties including Cardiology, Gastroenterology and Hepatology, Obstetrics and Gynaecology, Oncology, Ophthalmology, Paediatrics, Orthopaedic Surgery and Hand and Reconstructive Microsurgery. The Hospital also provides organ transplant programmes for adults (in kidney, liver and pancreas) and is the only public hospital in Singapore to offer a paediatric kidney and liver transplant programme.

Staffed by a team of healthcare professionals who rank among the best in the field, the NUH offers quality patient care by embracing innovations and advances in medical treatment.

In 2004, the NUH became the first Singapore hospital to receive the Joint Commission International accreditation, an international stamp for excellent clinical practices in patient care and safety. Today, patient safety and good clinical outcomes remain the focus of the hospital as it continues to play a key role in the training of doctors, nurses and allied health professionals, and in translational research which paves the way for new cures and treatment, offering patients hope and a new lease of life.

A member of the National University Health System, it is the principal teaching hospital of the NUS Yong Loo Lin School of Medicine and the NUS Faculty of Dentistry.

For more information, please visit <http://www.nuh.com.sg/>.

About the National University Cancer Institute, Singapore

The National University Cancer Institute, Singapore (NCIS) offers a broad spectrum of cancer care and management covering both paediatric and adult cancers, with expertise in prevention, screening, diagnosis, treatment, rehabilitation and palliative care. The Institute's strength lies in the multi-disciplinary approach taken to develop a comprehensive and personalised plan for each cancer patient and his or her family. NCIS draws on the expertise of its specialists in the fields of haematology-oncology, radiation oncology, gynaecologic oncology, paediatric oncology, surgical oncology, oncology nursing, oncology pharmacy, palliative care, pathology, radiology, medical specialties including gastroenterology and hepatology, infectious diseases, pulmonary and critical care, psychiatry, epidemiology and public health as well as other allied health sciences. NCIS's strength in research allows patients to access drugs and devices before they are commercially available. NCIS is also closely affiliated with the Cancer Science Institute of Singapore, National University of Singapore.

For more information about the NCIS, please visit <http://www.ncis.com.sg>.